Skip to content
Loop Biz – Lifestyle
Author:
InflaRx N.V.
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
May 6, 2026
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
May 6, 2026
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
May 4, 2026
InflaRx to Report First Quarter 2026 Results on May 7, 2026
May 1, 2026
←
Previous Page
1
2